Guggenheim keeps C4 Therapeutics at Buy, cuts price target to $6
Guggenheim kept its Buy rating on C4 Therapeutics and lowered its price target from $7 to $6, based on the November 5 close of $2.95, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Guggenheim analysts retained their Buy recommendation on C4 Therapeutics shares and reduced the price target to $6 from $7. TradingView, citing Benzinga data, notes that the new target implies a 103.4% upside from the November 5 closing price of $2.95.
The revision is the only change in the bank's assessment, as the rating itself stayed unchanged. Updates of this kind mainly concern investors who follow the stock closely.
why it matters
Analyst rating updates like this are routine and usually have limited impact on the share price. For the broader market the item is informational rather than significant.
tags
instruments
sources
- Guggenheim maintains C4 Therapeutics at Buy, lowers price target to $6 from $7 — TradingView, 6 November 2026 at 16:20 UTC
- Guggenheim maintains Damora Therapeutics at Buy, lowers price target to $59 from $60 — TradingView, 6 November 2026 at 16:23 UTC
- Guggenheim maintains Enliven Therapeutics at Buy, keeps price target at $78 — TradingView, 6 November 2026 at 16:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗